Novo Nordisk A/S has initiated a Phase 1 clinical study for LX9851, an oral drug candidate for obesity treatment developed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE